GGrantIndex
← Search

Maternal Lifestyle Study 9-11 Year Follow-up

$634,798U10FY2003HDNIH

Women And Infants Hospital-Rhode Island, Providence RI

Investigators

Linked publications, trials & patents

Paper 38416515Paper 37726016Paper 37640232Paper 37105408Paper 36905529Paper 36732048Paper 35850744Paper 35850743Paper 35835616Paper 35715492Paper 35301420Paper 35296895Paper 35034096Paper 34999716Paper 34862339Paper 34743364Paper 34686832Paper 34473345Paper 33986149Paper 33953357Paper 33632932Paper 33402707Paper 33386337Paper 33038899Paper 32978526Paper 32934363Paper 32474029Paper 32111975Paper 31880687Paper 31691959Paper 31431654Paper 31229956Paper 30961990Paper 30738658Paper 30737489Paper 30641105Paper 30631138Paper 30576590Paper 30068412Paper 30062831Paper 30054344Paper 29945955Paper 29872859Paper 29795315Paper 29793869Paper 29702710Paper 29666163Paper 29654994Paper 29538362Paper 29360264Paper 29306493Paper 29246358Paper 28982710Paper 28697406Paper 28647272Paper 28600154Trial NCT01954082Trial NCT01954056Trial NCT01793129Trial NCT01793116Trial NCT01534481Trial NCT01467076Trial NCT01353313Trial NCT01223287Trial NCT01223261Trial NCT01222364Trial NCT01203501Trial NCT01203488Trial NCT01203475Trial NCT01203436Trial NCT01203423Trial NCT01203410Trial NCT01193270Trial NCT01192776Trial NCT01035697Trial NCT01030575Trial NCT01029353Trial NCT00882284Trial NCT00874393Trial NCT00874367Trial NCT00873847Trial NCT00614744Trial NCT00349726Trial NCT00233324Trial NCT00114543Trial NCT00109525Trial NCT00067613Trial NCT00063063Trial NCT00059540Trial NCT00016523Trial NCT00011362Trial NCT00009646Trial NCT00009633Trial NCT00009620Trial NCT00005777Trial NCT00005776Trial NCT00005775Trial NCT00005774Trial NCT00005773Trial NCT00005772

Abstract

[unreadable] DESCRIPTION (provided by applicant): Prenatal substance exposure continues to be a major public health problem that affects millions of children and places enormous financial and social burdens on society. The Maternal Lifestyle Study (MLS) is an interagency collaboration involving the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the Administration on Children, Youth and Families, and the Center for Substance Abuse Treatment. MLS is being conducted in four University sites: Miami, Tennessee at Memphis, Wayne State, and Brown; and it is the largest clinical prospective longitudinal study to date of prenatal drug exposure and child outcome. The follow-up cohort includes 658 exposed and 730 comparison children who have been studied through 7 years of age with 71% retention. This application is to continue the follow-up through age 11. One aim is to study the effects of prenatal cocaine/opiate exposure on immediate child outcomes that start in infancy (e.g. attention, relationship to parent, neuromotor, physiologic reactivity, arousal/regulation, and medical status) as well as latent effects on domains of function that emerge later and become salient as children reach school age (e.g. cognition, antisocial behavior, substance use onset, psychopathology, neuroendocrine function, and health disorders). This includes determining the effects of heavy cocaine exposure and controlling for exposure to other drugs (alcohol, marijuana, and tobacco), medical (e.g. physical growth) and environmental factors, gender, minority status, and study site. The second aim is to study a broader conceptualization of the consequences of maternal drug use that includes determining how drug effects, and the effects of the postnatal environment combine to affect child outcome, including specific aspects of the environment unique to the drug culture. As a major longitudinal study, MLS is important to the field of developmental science by contributing to our understanding of developmental processes in normal and at-risk children. MLS will also contribute to the field by addressing health indicators related to Healthy People 2010. Understanding the consequences of prenatal cocaine exposure and risky environments is crucial for treatment and public policy. [unreadable] [unreadable]

View original record on NIH RePORTER →